Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 12, 2024Frontiers in ImmunologyOpen Access

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPrerak TrivediGJGaurang JhalaDGDavid J. De George

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Trivedi et al. (2024) studied this question.

synapsesocial.com/papers/68e745a8b6db6435876be8efhttps://doi.org/10.3389/fimmu.2024.1370907
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice2020 · 65 citations
  2. 2Fundamental Mechanisms of Immune Checkpoint Blockade Therapy2018 · 3,144 citations
  3. 3Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes2016 · 251 citations
  4. 4Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions2011 · 576 citations
  5. 5Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement2022 · 33 citations